Key result
Long-term aspirin is linked to lower symptomatic atherosclerosis prevalence in arthritis patients.
Why the study?
The effect of long-term aspirin therapy on the prevalence of symptomatic atherosclerosis in arthritis patients was unclear.
Observational
May support duration-dependent effect in arthritis; hypothesis-generating and should not yet change practice.
To determine the effect of long-term aspirin therapy on the prevalence of symptomatic atherosclerosis, autopsy results from 44 arthritis patients taking aspirin were compared with a cohort from the general autopsy population. No decrease in the prevalence of symptomatic atherosclerosis was noted in patients with less than 8 years of arthritis, compared with controls. In contrast, the prevalence of symptomatic atherosclerosis was significantly decreased in arthritis patients with 8 or more years of arthritis and aspirin use. In these subjects, the prevalence of symptomatic atherosclerosis was inversely related to duration of arthritis. The inverse relationship between prevalence of symptomatic atherosclerosis and duration of aspirin therapy, as well as the decrease in all forms of symptomatic atherosclerosis, raise the possibility that this decrease is due to primary prevention of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Gregory D. Sloop (1998) conducted an observational in Arthritis. Long-term aspirin therapy vs. Cohort from the general autopsy population was evaluated on Prevalence of symptomatic atherosclerosis. Long-term aspirin therapy for 8 or more years in arthritis patients was associated with a significantly decreased prevalence of symptomatic atherosclerosis compared with controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: